Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction  by Daviskas, Evangelia et al.
Respiratory Medicine (2010) 104, 1645e1653ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedBeneficial effect of inhaled mannitol and cough in
asthmatics with mucociliary dysfunction*Evangelia Daviskas a,*, Sandra D. Anderson a, Stefan Eberl b, Iven H. Young aaDepartments of Respiratory & Sleep Medicine, 11 West Royal Prince Hospital, Missenden Rd, Camperdown, Sydney,
NSW 2050, Australia
b PET & Nuclear Medicine, Camperdown, Sydney, NSW 2050, Australia
Received 17 March 2010; accepted 27 May 2010
Available online 23 June 2010KEYWORDS
Asthma;
Mucociliary clearance;
Cough;
Inhaled mannitolAbbreviations: ICS, inhaled corticoste
* The study was funded by the Natio
* Corresponding author. Tel.: þ61 2
E-mail address: daviskas@med.usy
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.05.019Summary
Asthmatics with overproduction of mucus that is viscous and sticky have impaired mucociliary
clearance (MCC) leading to mucus plugs, and airway obstruction. Inhaled mannitol improves
mucus clearance in other hypersecretory diseases. This study investigated the effect of
mannitol and cough in asthmatics with mucociliary dysfunction.
Seven stable asthmatics, age 52  20 yr, lifelong non-smokers, without the diagnosis of bron-
chiectasis, with chronic cough and sputum production, treated with inhaled corticosteroids
participated in the study. MCC and cough clearance (CC) was measured on 4 visits: at baseline
(no cough or mannitol), with mannitol (240 and 480 mg) and cough control (no mannitol) over
total 90 min using a radioaerosol technique and imaging with a gamma camera. Cough clear-
ance was assessed after MCC by asking subjects to cough 100 times over 30 min. Premedication
with eformoterol (12 mg) on all visits protected all subjects from bronchoconstriction (fall in
FEV1 > 15%) in response to mannitol.
Mean (SD) clearance over 60 min increased from 5.5  5.6% at baseline and 7.3  6.6% with
cough control to 19.5  14.6% and 26.4  11.5% with 240 mg (p < 0.003) and 480 mg
(p < 0.0001) of mannitol respectively. Total clearance (MCC þ CC) over 90 min increased from
6.9  6.5% (baseline) and 12.6  8.3% without mannitol (cough control) to 34.6  13.5 and
36.6  10.4% with 240 and 480 mg mannitol respectively (p < 0.0001). Clearance over
90 min at baseline was not significantly different to cough control (p > 0.05). Mannitol
improved clearance in all lung regions (p < 0.005).
In conclusion, mannitol improved both mucociliary and cough clearance in asthmatics with
mucociliary dysfunction and ineffective cough clearance.
Clinical Trial registered with www.anzctr.org.au; Number ACTRN 12609001066279.aspx.
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1646 E. Daviskas et al.Introduction required antibiotics in the last four weeks prior to study.Mucociliary dysfunction is a pathophysiological feature of
the hypersecretory phenotype in asthma that is charac-
terised by persistent airway inflammation, hypertrophy of
the submucosal glands, hyperplasia and metaplasia of the
goblet cells.1e4 Mucociliary dysfuction in asthma is a result
of chronic excessive secretion of mucus. The mucus is
viscous and sticky,5,6 tethered to the goblet cells,7 difficult
to clear by ciliary action8 with potential to contribute to
airway obstruction, plug formation and bacterial colonisa-
tion.9 Mucins, the major constituents of mucus, are prod-
ucts of the MUC genes, such as MUC5AC, MUC5B and
MUC2,10,11 that are upregulated in asthma and their upre-
gulation occurs in response to Th2 lymphocytes, cytokines
and inflammatory mediators.9 The MUC5AC gene product is
a goblet cell mucin that is increased in asthma and is the
main constituent of the mucus plugs.3,7,12 Mucociliary
dysfunction in asthma is a problem that is underappre-
ciated despite the associated consequences and the fact
that many asthmatics die with airways blocked with
mucus.9,13,14
Hypersecretion ofmucus andmucociliary dysfunction remain
a problem for some asthmatics and there is a need for a treat-
ment to facilitate clearance of mucus. Abnormal mucociliary
clearance (MCC) and abnormal sputum physical properties are
commonly noted even in asthmatics receiving regular treatment
with ICS and b2 agonists.
6,8 Patients with excessive secretion of
mucus have dehydrated mucus as a result of an imbalance
between the mucus load and the water available at the airway
lumen.15,16 Inhaled mannitol, being an osmotic agent, improves
hydration of mucus and its physical properties such as visco-
elasticity and adhesivity. Inhaled mannitol has been shown to
facilitate clearance of mucus in diseases where MCC is impaired
such as bronchiectasis and cystic fibrosis.17e19 In addition,
inhaledmannitol,when administered in the short and long term,
has been shown to improve the quality of life and lung function
in these diseases.20,21 The bronchoconstricting effect of
mannitol in asthmatics is well described,22 but it can be
prevented with premedication with eformoterol.6,23 In a recent
study in asthmatics with excessive secretions, it was demon-
strated that inhalation of mannitol improved the hydration,
surface properties and rheology of sputum.6 The effect of
mannitol on the sputum properties was not dose dependent.6 In
the present study, we investigated the effect of two doses of
mannitol and cough on the mucociliary and cough clearance of
mucus in asthmatics with chronic cough and sputum production.
Methods
Participants
Seven subjects with stable asthma, age 52  20 yr, lifelong
non-smokers, who had daily cough and sputum production
for longer than one year participated in the study. All the
subjects were well known asthmatics to Specialists in
Respiratory Medicine and were referred to the study as
outpatients. Their characteristics and treatment are
shown in Table 1. Subjects were included in the study if
they had chronic asthma treated with ICS and FEV1 > 1.2 L.
None of the subjects had a respiratory infection orBronchiectasis was excluded in all subjects based on
a HRCT scan.
The study was approved by the Ethics Committee of
the Sydney South West Area Health Service (protocol No:
X07-0207) and was performed under the Clinical Trial
Notification (CTN) Scheme of the Therapeutics and Goods
Regulations (Trial Number: 2007/652). Consent was
obtained in writing from all subjects.
Study design
There were 5 visits. On visit 1 (Screening), medical history
and medications were recorded. Lung function was
measured before and after eformoterol (12 mg). A standard
bronchial challenge with mannitol was performed in
accordance with the approved protocol22 to ensure efor-
moterol provided protection against bronchoconstriction.
Subjects were eligible to proceed to subsequent visits if
they had a fall in FEV1 < 15% of the baseline value in
response to a cumulative dose of mannitol of 635 mg after
premedication with eformoterol (12 mg) (Table 1).
On visits 2e5, MCC and cough clearance were measured
using a radioaerosol technique over a total of 90 min on
each visit. Cough clearance was assessed after the
measurement of MCC (first 60 min) by asking the subject to
cough deeply 100 times over the following 30 min (4 coughs
per min). The four studies involved measurements: at
baseline; with 2 doses of mannitol 240 and 480 mg; and with
cough alone (cough control). A baseline study assessed MCC
without mannitol or any voluntary coughing throughout the
total 90 min. The cough control study assessed the effect of
cough without mannitol, therefore it involved the same
number of coughs as on the mannitol study days during the
intervention and during the cough clearance interval. On
the cough control study (no mannitol), during the inter-
vention period, subjects inhaled through the device loaded
with an empty capsule and they were asked to cough the
same number of times they did spontaneously on the
mannitol day when the cough was most frequent. The
clearance studies at baseline (no mannitol or cough) and in
response to mannitol (240 and 480 mg) were done in
a randomised order. Subjects were premedicated with
eformoterol 12 mg, using the Aeroliser DPI (Novartis
Pharmaceuticals Australia Pty Ltd), on all visits prior to
inhaling the radioaerosol. The procedures on each study
day are shown in Table 2. The five studies were done at
least 72 h apart.
Dry powder mannitol
Dry powder mannitol (Pharmaxis Ltd, Frenchs Forest, NSW
Australia) was inhaled from capsules using the low resis-
tance dry powder inhaler (RS01; Plastiape, Osnage, Italy).
Two doses of mannitol were delivered, 240 mg (6 capsules
of 40 mg) and 480 mg (12 capsules of 40 mg).
Measurement of lung function
Spirometry was measured using a SpiroScoreþ (Bird
healthcare, Melbourne, Australia). All subjects had
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Beneficial effect of inhaled mannitol and cough in asthmatics 1647reproducible spirometry values (Table 1). Predicted values
were taken from Quanjer et al.24
Measurement of mucociliary (MCC) and cough
clearance
Mucociliary and cough clearance were measured using
a radioaerosol technique and imaging with a gamma
camera as described previously.25,8,19 The radioaerosol,
99mTc-sulphur colloid (CIS-US Inc.; Bedford, MA, USA) was
generated by a jet nebuliser (mass median aerodynamic
diameter: 6.0 mm, span 2; Medic-Aid, Peckham, UK) at
8 L/min. Subjects inhaled the radioaerosol following
a controlled breathing pattern having a target volume of
450 mL and a target inspiratory time aimed to maximise
deposition in the conducting airways. The peak inspiratory
flow was aimed to be approximately 40 L/min. Five minutes
after the radioaerosol inhalation, simultaneous anterior
and posterior dynamic images, 1 min frame rate, were
taken with a dual-head gamma camera (E-CAM, Siemens,
IL, USA) and the subject in the supine position. A trans-
mission image was taken to delineate the lung fields using
a cobalt-57 sheet source.
All images were decay corrected to the imaging start
time. The anterior and posterior emission images were
combined to geometric mean (GM) images. The right lung
was divided into three regions: central, intermediate and
peripheral.26 The initial lung radioaerosol distribution was
characterised by the ratio of the counts per pixel in the
peripheral region to the counts per pixel in the central
region of the GM emission image defined as the penetration
index.
A mono- or bi-exponential function was fitted to the
curves obtained from the counts of the dynamic GM images,
using a nonlinear least squares method (IDL 5.0, research
systems Inc, Boulder, Co, USA). The total counts of the
whole right lung and defined regions in the first emission GM
image were taken as 100% retention. The counts of the
dynamic emission GM images, measured before and after
the intervention were expressed as percentage of the initial
counts. The % retention curves give an overall estimate of
the total clearance from start (100% retained). Activity that
has not been retained has cleared. Counts from the best fit
of the % retention curves were used to calculate total %
clearance over the specified intervals (counts at start of
interval  counts at end of interval)  100/counts at start
of interval.
Statistical analysis
A one-factor analysis of variance (ANOVA), with repeated
measures, was performed on the calculated total %
clearance at the same specified intervals on the four study
days. Post-hoc analysis was performed using Fisher PLSD
(protected least significant difference). Probability values
less than 0.05 were considered statistically significant.
Statistical analyses were performed using a statistical
package (Statview, Abacus Concepts Inc; Berkeley, CA,
USA). Pearson’s correlation analysis was performed
between the number of coughs and the magnitude of
clearance.
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Figure 1 Mean (SEM) % retention curves over 90 min in the
whole right lung at baseline (no mannitol and cough) (open
circles), cough control (no mannitol) (open triangles), mannitol
240 mg (closed circles) and mannitol 480 mg (closed triangles)
in 7 asthmatics. This graph demonstrates the impaired baseline
MCC and cough clearance and the increase in clearance in
response to mannitol during intervention, post intervention
1648 E. Daviskas et al.Results
Mucociliary clearance (MCC) was abnormal at <10% (normal
being approximately 30% per h25,27,28), in this group of
asthmatics with chronic cough and sputum production.
Inhaled mannitol increased MCC in the whole right lung and
defined regions. The increase in MCC with mannitol was
dose dependent in the central region but this increase was
not related to the number of coughs provoked by mannitol
during inhalation. Repetitive coughing alone was not
effective in clearing mucus, however, repetitive coughing
was very effective in the presence of mannitol and
enhanced overall clearance with both doses of 240 and
480 mg mannitol in all asthmatics subjects in this group.
Clearance was enhanced in all regions in the presence of
mannitol including the peripheral region.
Whole right lung clearance
Mean (SD) clearance over 60 min increased from
5.5  5.6% at baseline and 7.3  6.6% with cough control to
19.5  14.6% and 26.4  11.5% with 240 mg (p < 0.003) and
480 mg (p < 0.0001) of mannitol respectively (Fig. 1). The
initial clearance over 15 min was negligible (around 1%) on
all visits (Fig. 1). Clearance of mucus in response to
mannitol started to increase during the intervention period
compared to baseline and cough control (p < 0.001) and
continued to increase over 30 min post intervention
compared to baseline and cough control (p < 0.05). The
increase in clearance during the intervention (15 min) was
greater with 480 mg mannitol compared to 240 mg mannitol
(p < 0.0001) (Fig. 1). However, the difference in clearance
between the two doses of mannitol was not related to theand in association with repetitive coughing.
Beneficial effect of inhaled mannitol and cough in asthmatics 1649difference in the number of coughs provoked by mannitol
during inhalation (r Z 0.15, p > 0.7). There was no
significant difference between baseline and cough control
clearance during intervention (p > 0.5). Whole right lung
clearance over 45 min from start of the intervention
between 240 and 480 mg approached significance
(p Z 0.053) (Fig. 1).
Total clearance (MCC and Cough clearance) over 90 min
increased from 6.9  6.5% (baseline) and 12.6  8.3%
without mannitol (cough control) to 34.6  13.5% and
36.6  10.4% with 240 and 480 mg mannitol respectively
(p < 0.0001). Cough control (no mannitol) clearance over
90 min was not significantly different to baseline
(p > 0.05).
Only 2 subjects out of seven had no increase in clearance
after the 240 mg, while all subjects had an increase in
clearance after 480 mg mannitol over 45 min from start of
inhalation (Fig. 2A). However, when repetitive coughing
was followed 30 min after mannitol inhalation all subjects
had an increase with both doses (Fig. 2B).
Regional clearance
Inhaled mannitol increased clearance in all regions,
central, intermediate and peripheral region (Fig. 3).
Central region
Mean (SD) clearance increased from 1.3  3.5% at base-
line to 13.8  15.8% with 240 mg (p < 0.03) and to
27.3  16.5% with 480 mg mannitol (p < 0.0001) over 60 min
(Fig. 3). Clearance with 480 mg was significantly greater
compared to clearance with 240 mg (p < 0.015). Total
clearance (MCC and Cough clearance) over 90 min
increased from 2.7  4.7% at baseline to 14.4  11.8% with
cough control (no mannitol) (p < 0.02) and to 40.7  10.9%
and 44.1  10.9% with 240 and 480 mg respectively
(p < 0.0001) (Fig. 3). There was no mannitol dose effect in
the total clearance when MCC was followed by cough
clearance (p > 0.4) (Fig. 3).Figure 2 Individual data demonstrating (A) the increase in MCC ov
(MCC þ cough clearance (CC)) in response to 240 and 480 mg mann
lung.Intermediate and peripheral region
Total clearance (MCC and Cough clearance) over 90 min was
increased from 10.4  9.3% at baseline and 10.5  6.2%
with cough control to 28.5  13.7% and 29.8  10.7% with
240 and 480 mg respectively (p < 0.0001) in the interme-
diate region (Fig. 3). In the peripheral region clearance
over 90 min increased from 18.8  9.7% at baseline and
13.3  11.1% with cough control to 31.0  21.7% and
33.4  11.0% with 240 and 480 mg respectively (p < 0.004).
There was no mannitol dose effect in clearance of mucus at
any interval in the intermediate or peripheral region
(p > 0.1) (Fig. 3).
Coughing provoked by mannitol
The number of coughs provoked by mannitol during the
intervention was dose dependent:Mean (SD) number of
coughs was 14.4 9.4 and 30.1 24.0 with mannitol 240 and
480 mg respectively (p Z 0.035) (Table 3). However, the
difference in clearance between the two doses in the central
region, both during intervention (15 min) and over total of
45 min, was not related to the difference in the number in
coughs (r Z 0.22, p > 0.6 and r Z 0.058, p > 0.9 respec-
tively) (Fig. 4). In addition, there was no significant corre-
lation found between the magnitude of clearance in the
whole right lung and central region with each mannitol dose
and the number of coughs provoked by mannitol (p > 0.3).
The number of coughs provoked by mannitol 240 mg during
intervention was not significantly different to the number of
spontaneous coughs at baseline (4.6  7.3) (p > 0.15).
Radioaerosol distribution
There was no significant difference in the radioaerosol
distribution in all study days as defined by the penetration
index (PI) (baseline: 30.2  6.4; cough control: 29.8  6.5;
mannitol 240 mg: 29.7  7.6; mannitol 480 mg: 29.2  7.6%,
p > 0.2).er 45 min from start of intervention and (B) the total clearance
itol compared to baseline and cough control in the whole right
Figure 3 Mean (SEM) % retention curves over 90 min in the Central (A), Intermediate (B) and Peripheral region (C) at baseline
(open circles), cough control (open triangles), mannitol 240 mg (closed circles) and mannitol 480 mg (closed triangles) in 7 asth-
matics. This graph demonstrates the impaired baseline MCC and cough clearance and the increase in clearance in response to
mannitol in all regions. Repetitive coughing alone had a small effect in the central region only compared to baseline. MCC with
480 mg mannitol was greater compared to 240 mg in the central region only.
1650 E. Daviskas et al.Discussion
The key findings in this study were that inhaled mannitol,
administered after premedication with eformoterol,
improved mucociliary and cough clearance in asthmatics
with excessive secretions and mucociliary dysfunction.
Premedication with eformoterol protected these asth-
matics treated regularly with ICS from any significant
bronchoconstriction in response to mannitol and it was well
tolerated. The inhalation of mannitol improved MCC in all
lung regions. This effect was dose dependent only in the
central region, an area that contains predominantly the
larger airways. Cough alone did not significantly improveTable 3 Mean  SD number of coughs in each period.
Study day During intervention
(15 min period)
Baseline 4.6  7.3a
Mannitol 240 mg 14.4  9.4a
Mannitol 480 mg 30.1  24.0a
Cough control 32.1  23.4b
a Spontaneous.
b Voluntary.clearance of mucus, however, in the presence of mannitol
cough markedly enhanced clearance in these asthmatics.
As inhaled mannitol can potentially cause bronchocon-
striction in asthmatics it is essential that they are pre-
medicated with an appropriate bronchodilator if they are
to be administered mannitol as a treatment for mucociliary
dysfunction. It is also essential to assess how well they are
protected against bronchoconstriction in response to
mannitol using a standard protocol with maximum dose of
635 mg.22 All subjects in the present study were pre-
medicated with 12 mg eformoterol, prior to inhaling
mannitol on all visits. On the screening visit, none of
the subjects had significant bronchoconstriction afterPost intervention
(30 min period)
Cough clearance
(30 min period)
4.3  8.1a 0
3.4  7.8a 100b
1.3  2.6a 100b
0.7  1.3a 100b
Figure 4 This figure demonstrates the lack of any significant correlation between the difference in clearance and the difference
in number coughs provoked by 480 and 240 mg of mannitol during intervention (15 min) and over 45 min in the central lung region
where cough could be most effective.
Beneficial effect of inhaled mannitol and cough in asthmatics 1651635 mg mannitol following the standard protocol for
administration.22
Eformoterol has been found to have no acute effect on
changing the sputum properties in a similar group of asth-
matics6 and it did not appear to have an acute effect on
baseline MCC in the asthmatics in the present study.
Baseline MCC was abnormal despite the chronic regular
treatment with ICS and LABA’s and the premedication with
eformoterol. The mean MCC was less than 10% per hour.
This value is significantly less than that measured in healthy
subjects and in asthmatics without mucociliary dysfunction
(>30% per hour) measured with central deposition of the
radioaerosol.27 As eformoterol was administered in all
studies, it is reasonable to assume that the increase in
clearance in the presence of mannitol was related to
mannitol and not to eformoterol. These findings, of
abnormal MCC and lack of any stimulation of MCC with
eformoterol, are consistent with previous findings in asth-
matics treated in the short (5 days) or in the long term (>2
years) with ICS.8,29 Mucociliary clearance in the asthmatics
with excessive secretions in the present study was as
abnormal as we have measured in patients with bronchi-
ectasis17,30 and cystic fibrosis.31
We chose to study the effect of 240 and 480 mg of
mannitol on MCC and cough clearance based on the results
of previous studies.6,19 MCC in response to mannitol was
dose dependent in the central region only. Mean MCC in the
central region over 45 min from the start of mannitol
inhalation was approximately 10% greater with double the
dose (Fig. 3A). All but 2 subjects had an increase in MCC
with 240 mg mannitol while all subjects had an increase in
MCC with 480 mg (Fig. 2A). Although the higher dose of
mannitol caused an increased number of coughs, the
increase in MCC was not related to the number coughs that
occurred mostly during the administration of mannitol. This
lack of correlation is consistent with all our previous studies
using mannitol.17,19,30 Although cough could be the domi-
nant factor in increasing clearance, the lack of any corre-
lation implies that ciliary activity or some other factors play
a role as well. It is hard to know how much of the measuredclearance over 45 min is due to cough and how much is due
to ciliary activity. When MCC was followed by repetitive
voluntary coughing over 30 min however, there was no
significant difference in the magnitude of the overall
clearance over 90 min with the two doses of mannitol.
Repetitive voluntary coughing without mannitol (cough
control study) had a small but significant effect in the
central region compared to baseline showing accumulation
of mucus in the absence of coughing and mannitol (Fig. 3A).
However, total clearance in this region, where cough could
be mostly effective, over 90 min was still quite impaired. It
appeared that in the presence of mannitol, the effective-
ness of cough was restored quickly even with the lower
dose of 240 mg mannitol. Similar findings of the effect of
different doses of mannitol on the cough clearance were
observed in patients with bronchiectasis.19 The increase in
clearance with mannitol is consistent with an improvement
in the surface and rheological properties after mannitol
inhalation observed in a similar group of asthmatics.6
MCC was improved after inhalation of mannitol in all
lung regions including the peripheral region. The peripheral
region, as defined by our method,26 contains predominantly
the small airways where cough cannot increase the airflow
velocity sufficiently to transport mucus. Deposition studies
have shown that inhaled mannitol (particle size 3 mm)
deposits in a diffuse manner in the lung.32,33 If mannitol can
stimulate MCC in the small airways where mucus is most
likely to obstruct airflow and where mucus plugs are most
likely to be formed, it may be of great benefit to this type
of asthmatic.
We did not investigate the inflammatory cell profile or the
ciliary function in these asthmatics. There is evidence
however that asthmatics with chronic hypersecretion of
mucus have, in addition to increased eosinophils, increased
numbers of neutrophils as seen in severe asthmatics.34 In
addition, there is evidence of ciliary disorientation in
patients with moderate to severe stable asthma.35 This is
consistent with the impaired MCC observed in asthmatics in
the previous8 and the present study. These asthmatics with
chronic secretion of mucus and mucociliary dysfunction are
1652 E. Daviskas et al.potentially more susceptible to infections and at increased
risk of developing bacterial colonisation of the airway with
consequent damage of the airway wall. A recent study in
severe asthma has shown that 40% of subjects with HRCT
scan abnormalities have bronchial wall dilatation.36 There-
fore, an additional benefit of early treatment of mucociliary
dysfunction in asthma may be in preventing damage of the
airway wall and development of bronchiectasis.
Inhaled mannitol, may be the preferred treatment in
stable asthmatics with excessive secretions while on
regular treatment with ICS who demonstrate protection
against significant bronchoconstriction in response to
mannitol after premedication with an appropriate bron-
chodilator. If an osmotic agent, such as mannitol, can be
safely administered, the benefit would be increased
hydration of mucus, reduction in the sputum surface
properties and rheology all resulting in improved clearance
of mucus. An increase in hydration of mucus is necessary
when the load of mucus in the airways is increased
compared to normal (2% solids).15,16 We found the solids
content to be around 7% in a similar group of asthmatics.6
In conclusion, inhaled mannitol improved both muco-
ciliary and cough clearance in asthmatics with chronic
cough, sputum production and marked mucociliary
dysfunction. Mannitol improved clearance in all lung
regions including the peripheral region that has predomi-
nantly small airways where cough is not effective in
clearing mucus. The findings of the present study have
clinical implications for the treatment of the hyper-
secretory phenotype in asthma that is often ignored but
may need additional treatment to avoid the detrimental
consequences of mucociliary dysfunction.Acknowledgements
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